The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology. 2018; 67: 328-357https://doi.org/10.1002/hep.29367
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.
Cancer. 2016; 122: 1312-1337https://doi.org/10.1002/cncr.29936
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Hepatology. 2016; 64: 73-84https://doi.org/10.1002/hep.28431
Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis.
J Carcinog. 2017; 16: 1https://doi.org/10.4103/jcar.JCar_9_16
Fibrosis-dependent mechanisms of hepatocarcinogenesis.
Hepatology. 2012; 56: 769-775https://doi.org/10.1002/hep.25670
Mezale D, Strumfa I, Vanags A, Mezals,Matiss ; Fridrihsone,Ilze ; Strumfs,Boriss ; Balodis,Dainis. Non-Alcoholic Steatohepatitis, Liver Cirrhosis and Hepatocellular Carcinoma: The Molecular Pathways | IntechOpen. Liver Cirrhosis, 2018. https://doi.org/10.5772/intechopen.68771.
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
Aliment Pharmacol Ther. 2018; 48: 696-703https://doi.org/10.1111/apt.14937
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.
Cancer Cell. 2016; 30: 879-890https://doi.org/10.1016/j.ccell.2016.11.004
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
Int J Cancer. 2011; 128: 2436-2443https://doi.org/10.1002/ijc.25797
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol. 2016; 14 (): 124-131https://doi.org/10.1016/j.cgh.2015.07.019
Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection.
Hepatol Res. 2017; 47: 405-418https://doi.org/10.1111/hepr.12762
Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Alimentary Pharmacology & Therapeutics. 2020; 52: 1185-1194https://doi.org/10.1111/apt.16016
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.
World J Hepatol. 2017; 9: 533-543https://doi.org/10.4254/wjh.v9.i11.533
Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.
World Journal of Hepatology. 2015; 7: 2384-2388https://doi.org/10.4254/wjh.v7.i22.2384
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Clin Gastroenterol Hepatol. 2020; 18 (): 728-735https://doi.org/10.1016/j.cgh.2019.11.012
The Obesity Epidemic–Understanding the Disease and the Treatment.
N Engl J Med. 2016; 374: 177-179https://doi.org/10.1056/NEJMe1514957
Adipose tissue, obesity and non-alcoholic fatty liver disease.
Minerva Endocrinol. 2017; 42: 92-108https://doi.org/10.23736/S0391-1977.16.02563-3
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.
Hepatology. 2009; 49: 851-859https://doi.org/10.1002/hep.22734
Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC.
J Hepatol. 2015; 63: 93-101https://doi.org/10.1016/j.jhep.2015.01.024
Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.
Br J Surg. 2013; 100: 113-121https://doi.org/10.1002/bjs.8963
Changing trends in malignant transformation of hepatocellular adenoma.
Gut. 2011; 60: 85-89https://doi.org/10.1136/gut.2010.222109
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?.
Arch Pathol Lab Med. 2008; 132: 1761-1766https://doi.org/10.1043/1543-2165-132.11.1761
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
Hepatology. 2010; 51: 1820-1832https://doi.org/10.1002/hep.23594
Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma.
Pathol Oncol Res. 2014; 20: 667-675https://doi.org/10.1007/s12253-014-9747-0
Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment.
J Clin Biochem Nutr. 2011; 49: 153-158https://doi.org/10.3164/jcbn.10-149
Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity.
Front Biosci (Landmark Ed). 2012; 17: 2356-2370
Metabolic signals and innate immune activation in obesity and exercise.
Exerc Immunol Rev. 2015; 21: 58-68
Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling.
Nat Immunol. 2011; 12: 408-415https://doi.org/10.1038/ni.2022
Diabetes and cancer–an AACE/ACE consensus statement.
Endocr Pract. 2013; 19: 675-693https://doi.org/10.4158/EP13248.CS
Toll-like receptor status in obesity and metabolic syndrome: a translational perspective.
J Clin Endocrinol Metab. 2014; 99: 39-48https://doi.org/10.1210/jc.2013-3092
Adipocyte-Macrophage Cross-Talk in Obesity.
Adv Exp Med Biol. 2017; 960: 327-343https://doi.org/10.1007/978-3-319-48382-5_14
CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).
Semin Immunopathol. 2014; 36: 55-71https://doi.org/10.1007/s00281-013-0407-3
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift.
Diab Vasc Dis Res. 2019; 16: 118-127https://doi.org/10.1177/1479164119827611
Metabolic Syndrome in Heart Failure: Friend or Foe?.
Heart Failure Clinics. 2019; 15: 349-358https://doi.org/10.1016/j.hfc.2019.02.004
Insulin Resistance in Children.
Front Endocrinol (Lausanne). 2019; 10: 342https://doi.org/10.3389/fendo.2019.00342
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview.
Int J Mol Sci. 2019; 20https://doi.org/10.3390/ijms20081948
Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?.
Liver Int. 2016; 36: 1563-1579https://doi.org/10.1111/liv.13185
Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study.
PLoS One. 2017; 12https://doi.org/10.1371/journal.pone.0174291
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.
Gut. 2005; 54: 533-539https://doi.org/10.1136/gut.2004.052167
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.
Ann Transl Med. 2017; 5https://doi.org/10.21037/atm.2017.04.41
Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients.
J Gastroenterol Hepatol. 2017; 32: 1100-1106https://doi.org/10.1111/jgh.13647
The role of hepatokines in metabolism.
Nat Rev Endocrinol. 2013; 9: 144-152https://doi.org/10.1038/nrendo.2012.258
Hepatokines: unlocking the multi-organ network in metabolic diseases.
Diabetologia. 2015; 58: 1699-1703https://doi.org/10.1007/s00125-015-3634-4
Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism.
Cell Metabolism. 2015; 22: 1078-1089https://doi.org/10.1016/j.cmet.2015.09.023
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Nat Rev Endocrinol. 2017; 13: 509-520https://doi.org/10.1038/nrendo.2017.56
Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions.
Int J Mol Sci. 2017; 18https://doi.org/10.3390/ijms18081649
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.
Int J Mol Sci. 2018; 19https://doi.org/10.3390/ijms19020431
Regulation of lipid metabolism by angiopoietin-like proteins.
Curr Opin Lipidol. 2016; 27: 249-256https://doi.org/10.1097/MOL.0000000000000290
Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation.
Nutr Diabetes. 2018; 8: 21https://doi.org/10.1038/s41387-018-0032-2
The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity.
J Biol Chem. 2006; 281: 934-944https://doi.org/10.1074/jbc.M506519200
Angiopoietin-related growth factor antagonizes obesity and insulin resistance.
Nat Med. 2005; 11: 400-408https://doi.org/10.1038/nm1214
Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis.
Metab Clin Exp. 2009; 58: 547-551https://doi.org/10.1016/j.metabol.2008.11.016
The association between dietary antioxidants and adipokines level among obese women.
Diabetes Metab Syndr. 2019; 13: 1369-1373https://doi.org/10.1016/j.dsx.2019.02.022
Identification of genes differentially expressed in human hepatocellular carcinoma by a modified suppression subtractive hybridization method.
Int J Cancer. 2004; 112: 239-248https://doi.org/10.1002/ijc.20363
Hepatocellular Carcinoma-Associated Protein TD26 Interacts and Enhances Sterol Regulatory Element-Binding Protein 1 Activity to Promote Tumor Cell Proliferation and Growth.
Hepatology. 2018; 68: 1833-1850https://doi.org/10.1002/hep.30030
ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives.
Horm Metab Res. 2017; 49: 343-349https://doi.org/10.1055/s-0043-102950
The Correlation Between Circulating Betatrophin and Insulin Resistance in General Population: A Meta-Analysis.
Horm Metab Res. 2017; 49: 760-771https://doi.org/10.1055/s-0043-108911
Increased Serum ANGPTL8 Concentrations in Patients with Prediabetes and Type 2 Diabetes.
J Diabetes Res. 2017; 2017: 8293207https://doi.org/10.1155/2017/8293207
Angiopoietin-like protein 8: An attractive biomarker for the evaluation of subjects with insulin resistance and related disorders.
Diabetes Research and Clinical Practice. 2017; 133: 168-177https://doi.org/10.1016/j.diabres.2017.08.025
On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity.
J Lipid Res. 2019; 60: 783-793https://doi.org/10.1194/jlr.M088807
Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family.
Biochem Biophys Res Commun. 2013; 430: 1126-1131https://doi.org/10.1016/j.bbrc.2012.12.025
The Effects of Serum ANGPTL8/betatrophin on the Risk of Developing the Metabolic Syndrome – A Prospective Study.
Scientific Reports. 2016; 6: 28431https://doi.org/10.1038/srep28431
Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
Hepatology. 2016; 64: 1637-1651https://doi.org/10.1002/hep.28773
ANGPTL2 promotes tumor metastasis in hepatocellular carcinoma.
J Gastroenterol Hepatol. 2015; 30: 396-404https://doi.org/10.1111/jgh.12702
Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma.
Mol Cancer. 2014; 13: 196https://doi.org/10.1186/1476-4598-13-196
Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease.
J Invest Surg. 2016; 29: 266-274https://doi.org/10.3109/08941939.2016.1149640
Serum Fetuin-A Associated With Fatty Liver Index, Early Indicator of Nonalcoholic Fatty Liver Disease: A Strobe-Compliant Article.
Medicine (Baltimore). 2015; 94: e1517https://doi.org/10.1097/MD.0000000000001517
Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients.
Clin Sci. 2013; 125: 391-400https://doi.org/10.1042/CS20120542
The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans.
Am J Physiol Endocrinol Metab. 2018; 314: E266-E273https://doi.org/10.1152/ajpendo.00262.2017
Iroz A, Couty J-P, Postic C. Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia 2015;58:1699–703. https://doi.org/10.1007/s00125-015-3634-4.
Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance.
Nature Medicine. 2012; 18: 1279-1285https://doi.org/10.1038/nm.2851
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?.
Acta Diabetol. 2019; 56: 385-396https://doi.org/10.1007/s00592-018-1266-0
Role of glucose effectiveness in the determination of glucose tolerance.
Diabetes Care. 1996; 19: 1018-1030https://doi.org/10.2337/diacare.19.9.1018
Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients.
Front Endocrinol (Lausanne). 2019; 10https://doi.org/10.3389/fendo.2019.00270
Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice.
Am J Transl Res. 2019; 11: 1498-1509
Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects.
Liver Int. 2015; 35: 925-935https://doi.org/10.1111/liv.12478
Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
Endocrine. 2017; 58: 246-252https://doi.org/10.1007/s12020-017-1417-z
Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.
Hepatology. 2014; 60: 858-871https://doi.org/10.1002/hep.27016
Fibroblast Growth Factor Signaling in Metabolic Regulation.
Front Endocrinol (Lausanne). 2015; 6: 193https://doi.org/10.3389/fendo.2015.00193
The Fibroblast Growth Factor signaling pathway.
Wiley Interdiscip Rev Dev Biol. 2015; 4: 215-266https://doi.org/10.1002/wdev.176
Functions of fibroblast growth factors and their receptors.
Curr Biol. 1995; 5: 500-507https://doi.org/10.1016/s0960-9822(95)00102-3
Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors.
Biomed Res Int. 2016; 2016: 8323747https://doi.org/10.1155/2016/8323747
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.
Mol Cell Biol. 2007; 27: 3417-3428https://doi.org/10.1128/MCB.02249-06
Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis.
Gene. 2018; 674: 57-69https://doi.org/10.1016/j.gene.2018.06.053
Mapping of the fibroblast growth factors in human white adipose tissue.
J Clin Endocrinol Metab. 2010; 95: 2451-2457https://doi.org/10.1210/jc.2009-2049
Mechanisms underlying differential responses to FGF signaling.
Cytokine Growth Factor Rev. 2005; 16: 233-247https://doi.org/10.1016/j.cytogfr.2005.01.007
Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease.
J Gastroenterol. 1997; 32: 119-121
Metabolic Regulator βKlotho Interacts with Fibroblast Growth Factor Receptor 4 (FGFR4) to Induce Apoptosis and Inhibit Tumor Cell Proliferation.
J Biol Chem. 2010; 285: 30069-30078https://doi.org/10.1074/jbc.M110.148288
Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21.
J Biol Chem. 2007; 282: 26687-26695https://doi.org/10.1074/jbc.M704165200
Specificity for Fibroblast Growth Factors Determined by Heparan Sulfate in a Binary Complex with the Receptor Kinase.
J Biol Chem. 1999; 274: 15947-15952https://doi.org/10.1074/jbc.274.22.15947
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
Hepatology. 2013; 57: 1394-1406https://doi.org/10.1002/hep.26225
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
Gut. 2018; 67: 1881-1891https://doi.org/10.1136/gutjnl-2017-314307
Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Oncotarget. 2016; 7: 52329-52339https://doi.org/10.18632/oncotarget.10750
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2018; 391: 1174-1185https://doi.org/10.1016/S0140-6736(18)30474-4
Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.
PLoS ONE. 2015; 10e0122961https://doi.org/10.1371/journal.pone.0122961
Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.
Dig Dis Sci. 2013; 58: 1916-1922https://doi.org/10.1007/s10620-013-2609-x
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
BMC Cancer. 2012; 12: 56https://doi.org/10.1186/1471-2407-12-56
Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
Clin Transl Gastroenterol. 2020; 11https://doi.org/10.14309/ctg.0000000000000131
Fibroblast growth factor 21 corrects obesity in mice.
Endocrinology. 2008; 149: 6018-6027https://doi.org/10.1210/en.2008-0816
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Diabetes. 2009; 58: 250-259https://doi.org/10.2337/db08-0392
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.
Diabetes. 2008; 57: 1246-1253https://doi.org/10.2337/db07-1476
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
J Hepatol. 2010; 53: 934-940https://doi.org/10.1016/j.jhep.2010.05.018
Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes.
BMJ Open Diabetes Res Care. 2019; 7e000776https://doi.org/10.1136/bmjdrc-2019-000776
Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress.
BMC Gastroenterol. 2013; 13: 67https://doi.org/10.1186/1471-230X-13-67
Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?.
Adv Med Sci. 2019; 64: 280-284https://doi.org/10.1016/j.advms.2019.02.005
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.
PLoS ONE. 2015; 10e0131664https://doi.org/10.1371/journal.pone.0131664
Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of HNF1alpha with decreased levels of hepassocin in human hepatocellular carcinoma.
J Biol Chem. 2009; 284: 13335-13347https://doi.org/10.1074/jbc.M806393200
Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
Endocr Metab Immune Disord Drug Targets. 2019; 19: 185-188https://doi.org/10.2174/1871530318666180716100543
The role of hepassocin in the development of non-alcoholic fatty liver disease.
J Hepatol. 2013; 59: 1065-1072https://doi.org/10.1016/j.jhep.2013.06.004
Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization.
PLoS ONE. 2013; 8e58084https://doi.org/10.1371/journal.pone.0058084
Unsaturated Fatty Acids Increase the Expression of Hepassocin through a Signal Transducer and Activator of Transcription 3-Dependent Pathway in HepG2 Cells.
Lipids. 2018; 53: 863-869https://doi.org/10.1002/lipd.12099
Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle.
Mol Cell Endocrinol. 2018; 470: 26-33https://doi.org/10.1016/j.mce.2017.10.014
Recombinant human hepassocin stimulates proliferation of hepatocytes in vivo and improves survival in rats with fulminant hepatic failure.
Gut. 2010; 59: 817-826https://doi.org/10.1136/gut.2008.171124
LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma.
Oncogene. 2004; 23: 1939-1949https://doi.org/10.1038/sj.onc.1207306
Deletion of HNF1α in hepatocytes results in fatty liver-related hepatocellular carcinoma in mice.
FEBS Lett. 2017; 591 ()https://doi.org/10.1002/1873-3468.12689
Human plasma retinol-binding protein (RBP4) is also a fatty acid-binding protein.
Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863: 458-466https://doi.org/10.1016/j.bbalip.2018.01.010
Ligand-dependent regulation of intracellular protein transport: effect of vitamin a on the secretion of the retinol-binding protein.
J Cell Biol. 1983; 96: 907-910https://doi.org/10.1083/jcb.96.3.907
Characterization of Vitamin A Metabolome in Human Livers With and Without Nonalcoholic Fatty Liver Disease.
J Pharmacol Exp Ther. 2019; 370: 92-103https://doi.org/10.1124/jpet.119.258517
RBP4: a controversial adipokine.
Eur J Endocrinol. 2011; 165: 703-711https://doi.org/10.1530/EJE-11-0431
Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.
Obesity (Silver Spring). 2009; 17: 1696-1701https://doi.org/10.1038/oby.2009.89
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease.
J Clin Gastroenterol. 2009; 43: 985-989https://doi.org/10.1097/MCG.0b013e3181a0998d
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease.
Hepatology. 2009; 49: 1926-1934https://doi.org/10.1002/hep.22896
Retinol-Binding Protein 4 Induces Hepatic Mitochondrial Dysfunction and Promotes Hepatic Steatosis.
J Clin Endocrinol Metab. 2016; 101: 4338-4348https://doi.org/10.1210/jc.2016-1320
Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease.
Diabetes Metab. 2019; https://doi.org/10.1016/j.diabet.2019.04.009
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis.
Dig Liver Dis. 2011; 43: 404-410https://doi.org/10.1016/j.dld.2010.12.013
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.
N Engl J Med. 2006; 354: 2552-2563https://doi.org/10.1056/NEJMoa054862
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.
Nature. 2005; 436: 356-362https://doi.org/10.1038/nature03711
Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease.
Clin Endocrinol (Oxf). 2008; 68: 555-560https://doi.org/10.1111/j.1365-2265.2007.03072.x
Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Diabetes Res Clin Pract. 2008; 79: 185-190https://doi.org/10.1016/j.diabres.2007.08.016
Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis.
Clin Endocrinol (Oxf). 2009; 70: 60-65https://doi.org/10.1111/j.1365-2265.2008.03295.x
Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease.
Hepatol Res. 2009; 39: 972-978https://doi.org/10.1111/j.1872-034X.2009.00534.x
Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol. 2009; 7: 575-579https://doi.org/10.1016/j.cgh.2008.12.031
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Nutrients. 2017; 10https://doi.org/10.3390/nu10010029
Immunological functions of leptin and adiponectin.
Biochimie. 2012; 94: 2082-2088https://doi.org/10.1016/j.biochi.2012.05.018
Obesity affects the liver – the link between adipocytes and hepatocytes.
Digestion. 2011; 83: 124-133https://doi.org/10.1159/000318741
An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.
Cell Metab. 2013; 17: 790-797https://doi.org/10.1016/j.cmet.2013.03.019
Adiponectin as a biomarker of the metabolic syndrome.
Circ J. 2004; 68: 975-981
Pattern of Expression of Adiponectin Receptors in Human Liver and its Relation to Nonalcoholic Steatohepatitis.
OBES SURG. 2008; 19: 467https://doi.org/10.1007/s11695-008-9701-x
Clinical picture, insulin resistance, and adipocytokines profiles of nonalcoholic steatohepatitis (NASH) patients in Indonesia.
Acta Medica Indonesiana. 2009; 41: 6-10
Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis.
JAMA. 2009; 302: 179-188https://doi.org/10.1001/jama.2009.976
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Metabolism. 2011; 60: 313-326https://doi.org/10.1016/j.metabol.2010.09.003
Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort.
Sci Rep. 2015; 5: 13058https://doi.org/10.1038/srep13058
Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective.
PLoS ONE. 2019; 14 ()https://doi.org/10.1371/journal.pone.0214436
Adiponectin in insulin resistance: lessons from translational research.
Am J Clin Nutr. 2010; 91: 258S-261Shttps://doi.org/10.3945/ajcn.2009.28449C
Adiponectin Signaling Pathways in Liver Diseases.
Biomedicines. 2018; 6https://doi.org/10.3390/biomedicines6020052
High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate–activated protein kinase.
Hepatology. 2008; 47: 677-685https://doi.org/10.1002/hep.21991
Associations of Adiponectin with Body Fat Distribution and Insulin Sensitivity in Nondiabetic Hispanics and African-Americans.
J Clin Endocrinol Metab. 2007; 92: 2665-2671https://doi.org/10.1210/jc.2006-2614
THE INDEPENDENT ASSOCIATION BETWEEN 25-HYDROXYVITAMIN D AND ADIPONECTIN AND ITS RELATION WITH BMI IN TWO LARGE COHORTS: the NHS and the HPFS.
Obesity (Silver Spring). 2012; 20: 186-191https://doi.org/10.1038/oby.2011.210
Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.
Metab Clin Exp. 2014; 63: 1542-1552https://doi.org/10.1016/j.metabol.2014.09.001
Total adiponectin in overweight and obese subjects and its response to visceral fat loss.
BMC Endocrine Disorders. 2019; 19: 55https://doi.org/10.1186/s12902-019-0386-z
Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
J Hepatol. 2015; 62: 405-411https://doi.org/10.1016/j.jhep.2014.08.040
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Ann Intern Med. 2016; 165: 305-315https://doi.org/10.7326/M15-1774
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
Diabetes, Obesity and Metabolism. 2010; 12: 365-383https://doi.org/10.1111/j.1463-1326.2009.01176.x
Adipokine expression in brown and white adipocytes in response to hypoxia.
J Endocrinol Invest. 2012; 35: 522-527https://doi.org/10.3275/7964
Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation.
Diabetes. 2007; 56: 901-911https://doi.org/10.2337/db06-0911
Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma.
Biol Chem. 2016; 397: 257-267https://doi.org/10.1515/hsz-2015-0265
Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Clin Cancer Res. 2010; 16: 967-977https://doi.org/10.1158/1078-0432.CCR-09-1487
Adiponectin knockout accentuates high fat diet-induced obesity and cardiac dysfunction: Role of autophagy.
Biochim Biophys Acta. 2013; 1832: 1136-1148https://doi.org/10.1016/j.bbadis.2013.03.013
Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
J Gastroenterol Hepatol. 2009; 24: 1669-1676https://doi.org/10.1111/j.1440-1746.2009.06039.x
Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.
Gastroenterology. 2010; 139 (): 1762-1773https://doi.org/10.1053/j.gastro.2010.07.001
The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients.
Hum Exp Toxicol. 2012; 31: 311-321https://doi.org/10.1177/0960327111431091
Clinical Significance of Serum Adiponectin and Resistin Levels in Liver Cirrhosis.
Ann Hepatol. 2018; 17: 286-299https://doi.org/10.5604/01.3001.0010.8659
Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.
Anticancer Res. 2016; 36: 5307-5314https://doi.org/10.21873/anticanres.11103
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.
Oncology. 2015; 88: 57-68https://doi.org/10.1159/000367971
High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo.
J Hepatol. 2005; 42: 666-673https://doi.org/10.1016/j.jhep.2004.12.024
TNFalpha up-regulates apelin expression in human and mouse adipose tissue.
FASEB J. 2006; 20: 1528-1530https://doi.org/10.1096/fj.05-5243fje
Apelin, a newly identified adipokine up-regulated by insulin and obesity.
Endocrinology. 2005; 146: 1764-1771https://doi.org/10.1210/en.2004-1427
The Apelin Receptor APJ in Hematopoietic Stem Cells/Progenitor Cells in the Early Stage of Non-Alcoholic Steatohepatitis.
J Clin Med Res. 2017; 9: 809-811https://doi.org/10.14740/jocmr3103w
The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma.
Anticancer Res. 2014; 34: 5313-5320
Apelin promotes hepatic fibrosis through ERK signaling in LX-2 cells.
Mol Cell Biochem. 2019; 460: 205-215https://doi.org/10.1007/s11010-019-03581-0
Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease.
J Res Med Sci. 2017; 22: 70https://doi.org/10.4103/jrms.JRMS_788_16
Plasma apelin levels in subjects with nonalcoholic fatty liver disease.
Metab Clin Exp. 2010; 59: 977-981https://doi.org/10.1016/j.metabol.2009.10.019
Apelin protects against liver X receptor-mediated steatosis through AMPK and PPARα in human and mouse hepatocytes.
Cell Signal. 2017; 39: 84-94https://doi.org/10.1016/j.cellsig.2017.08.003
Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection.
Anticancer Res. 2019; 39: 3025-3031https://doi.org/10.21873/anticanres.13435
APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Theranostics. 2019; 9: 5246-5260https://doi.org/10.7150/thno.34713
Chemerin is a novel adipokine associated with obesity and metabolic syndrome.
Endocrinology. 2007; 148: 4687-4694https://doi.org/10.1210/en.2007-0175
Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population.
J Clin Endocrinol Metab. 2009; 94: 3085-3088https://doi.org/10.1210/jc.2008-1833
Serum Chemerin Levels Vary with Time of Day and Are Modified by Obesity and Tumor Necrosis Factor-α.
Endocrinology. 2010; 151: 2590-2602https://doi.org/10.1210/en.2009-0794
Serum chemerin and vaspin in non-alcoholic fatty liver disease.
Scand J Gastroenterol. 2010; 45: 235-242https://doi.org/10.3109/00365520903443852
Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.
Scandinavian Journal of Gastroenterology. 2011; 46: 91-97https://doi.org/10.3109/00365521.2010.516452
Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease.
Pol J Pathol. 2017; 68: 117-127https://doi.org/10.5114/pjp.2017.69687
Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
Obesity (Silver Spring). 2016; 24: 2544-2552https://doi.org/10.1002/oby.21674
Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin.
Diabetes. 2009; 58 ()https://doi.org/10.2337/db08-1528
Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery.
J Clin Endocrinol Metab. 2010; 95: 2892-2896https://doi.org/10.1210/jc.2009-2374
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
European Journal of Clinical Investigation. 2017; 47: 7-18https://doi.org/10.1111/eci.12695
Relationship Between 12 Adipocytokines and Distinct Components of the Metabolic Syndrome.
J Clin Endocrinol Metab. 2018; 103: 1015-1023https://doi.org/10.1210/jc.2017-02085
Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis.
Endocrinology. 2013; 154: 1794-1801https://doi.org/10.1210/en.2012-2126
Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Anticancer Res. 2018; 38: 2649-2657https://doi.org/10.21873/anticanres.12507
Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver.
Experimental and Molecular Pathology. 2013; 95: 199-205https://doi.org/10.1016/j.yexmp.2013.07.009
Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease.
Eur J Endocrinol. 2013; 169: 547-557https://doi.org/10.1530/EJE-13-0112
Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma.
Clin Lab. 2011; 57: 879-885
Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma.
Int J Mol Sci. 2014; 15: 11294-11306https://doi.org/10.3390/ijms150711294
Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis.
Sci Rep. 2018; 8: 9242https://doi.org/10.1038/s41598-018-27543-6
Weight-reducing effects of the plasma protein encoded by the obese gene.
Science. 1995; 269: 543-546https://doi.org/10.1126/science.7624777
Leptin signaling, adiposity, and energy balance.
Ann N Y Acad Sci. 2002; 967: 379-388https://doi.org/10.1111/j.1749-6632.2002.tb04293.x
Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later?.
Nutrients. 2019; 11https://doi.org/10.3390/nu11112704
Congenital leptin deficiency is associated with severe early-onset obesity in humans.
Nature. 1997; 387: 903-908https://doi.org/10.1038/43185
Adipocytokines and liver disease.
J Gastroenterol. 2008; 43: 811-822https://doi.org/10.1007/s00535-008-2213-6
Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Diabetologia. 2016; 59: 30-43https://doi.org/10.1007/s00125-015-3769-3
Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern.
J Transl Med. 2019; 17: 310https://doi.org/10.1186/s12967-019-2060-7
Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis.
Hepatology. 2010; 52: 1713-1722https://doi.org/10.1002/hep.23892
Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis.
Horm Res. 2003; 60: 185-190https://doi.org/10.1159/000073231
SERUM LEPTIN LEVENS AND HEPATOCELLULAR CARCINOMA: REVIEW ARTICLE.
Arq Bras Cir Dig. 2016; 29: 276-278https://doi.org/10.1590/0102-6720201600040015
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice.
Hepatology. 2002; 35: 762-771https://doi.org/10.1053/jhep.2002.32029
Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma.
Clin Liver Dis. 2015; 19: 361-379https://doi.org/10.1016/j.cld.2015.01.012
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis.
Am J Physiol Gastrointest Liver Physiol. 2015; 308 ()https://doi.org/10.1152/ajpgi.00346.2014
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.
Cancer Res. 2007; 67: 2497-2507https://doi.org/10.1158/0008-5472.CAN-06-3075
Leptin Enhances Cholangiocarcinoma Cell Growth.
Cancer Res. 2008; 68: 6752-6761https://doi.org/10.1158/0008-5472.CAN-07-6682
Leptin and cancer.
J Cell Physiol. 2006; 207: 12-22https://doi.org/10.1002/jcp.20472
Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway.
Biochem Biophys Res Commun. 2005; 334: 1092-1101https://doi.org/10.1016/j.bbrc.2005.06.202
The role of resistin as a regulator of inflammation: Implications for various human pathologies.
Clin Immunol. 2009; 133: 157-170https://doi.org/10.1016/j.clim.2009.07.013
Resistin, an Adipokine with Potent Proinflammatory Properties.
The Journal of Immunology. 2005; 174: 5789-5795https://doi.org/10.4049/jimmunol.174.9.5789
Serum resistin (FIZZ3) protein is increased in obese humans.
J Clin Endocrinol Metab. 2003; 88: 5452-5455https://doi.org/10.1210/jc.2002-021808
Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.
J Clin Endocrinol Metab. 2003; 88: 6098-6106https://doi.org/10.1210/jc.2003-030898
Resistin in morbidly obese patients before and after gastric bypass surgery.
Nutr Hosp. 2017; 34: 1333-1337
Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels.
J Gastroenterol Hepatol. 2020; https://doi.org/10.1111/jgh.15029
The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy.
J Pediatr. 2020; 216 (): 117-127https://doi.org/10.1016/j.jpeds.2019.07.037
Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients.
Obes Surg. 2017; 27: 2151-2158https://doi.org/10.1007/s11695-017-2627-4
Resistin and Insulin Resistance: A Link Between Inflammation and Hepatocarcinogenesis.
Asian Pac J Cancer Prev. 2015; 16: 7139-7142
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
J Immunol. 2007; 178: 1748-1758https://doi.org/10.4049/jimmunol.178.3.1748
Visfatin levels in nonalcoholic fatty liver disease.
J Clin Lab Anal. 2012; 26: 115-119https://doi.org/10.1002/jcla.21491
Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease.
Med Princ Pract. 2017; 26: 251-257https://doi.org/10.1159/000455862
Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease.
Dig Dis Sci. 2009; 54: 1772-1777https://doi.org/10.1007/s10620-008-0539-9
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Pol J Pathol. 2010; 61: 147-153
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Horm Metab Res. 2019; 51: 602-607https://doi.org/10.1055/a-0897-8565
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Oncotarget. 2016; 7: 77968-77977https://doi.org/10.18632/oncotarget.12864
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Oncotarget. 2017; 8: 23427-23435https://doi.org/10.18632/oncotarget.15080
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Cancer Prev Res (Phila). 2011; 4: 2092-2100https://doi.org/10.1158/1940-6207.CAPR-11-0340
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Cytokine. 2017; 90: 54-59https://doi.org/10.1016/j.cyto.2016.10.007
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
J Hepatol. 2018; 69: 396-405https://doi.org/10.1016/j.jhep.2018.03.031
Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy.
J Clin Med. 2019; 8https://doi.org/10.3390/jcm8060815
Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Lipids Health Dis. 2017; 16: 180https://doi.org/10.1186/s12944-017-0566-7
Retinol binding protein-4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women.
Obesity (Silver Spring). 2013; 21: 170-177https://doi.org/10.1002/oby.20233
Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4.
Diabetes Care. 2007; 30: 1168-1172https://doi.org/10.2337/dc06-2323